Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Vactech Oy

Innovations for Health.

## Sitemaps

- [XML Sitemap](https://www.vactech.fi/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [World’s First Preventive Vaccine for Type 1 Diabetes](https://www.vactech.fi/) - Our patented type 1 diabetes vaccine is advancing in clinical trials, targeting a fast-growing global health challenge that affects over 15 million people.
- [Scientific Publications & Research Highlights](https://www.vactech.fi/publications/) - Explore Vactech’s peer-reviewed publications and key research on type 1 diabetes, enteroviruses, and vaccine innovation driving preventive healthcare.
- [Winning the Fight Against Type 1 Diabetes](https://www.vactech.fi/diabetes-vaccine/) - Vactech is revolutionizing prevention with a patented vaccine targeting enteroviruses linked to type 1 diabetes, myocarditis, meningitis, and celiac disease.
- [Multivalent Vaccine to Prevent Type 1 Diabetes](https://www.vactech.fi/t1d-vaccine/) - Vactech is developing a multivalent vaccine to prevent type 1 diabetes, targeting key enterovirus types (Coxsackie B serotypes) strongly linked to this disease.
- [Globally Recognized Science](https://www.vactech.fi/board-management/) - Our renowned scientific founders, recognized globally in immunology and virology, have secured significant international awards and strategic partnerships.
- [Join Us to Shape the Future](https://www.vactech.fi/careers/) - Join Vactech and help us unlock the future of immune health. Be part of a team pioneering new solutions for type 1 diabetes, celiac disease, and more.
- [Patented Vaccines and Diagnostics](https://www.vactech.fi/patents/) - Vactech owns patents for a type 1 diabetes vaccine, antivirals, and diagnostics, plus IP for virus-based solutions to treat and prevent celiac disease.
- [Strategic Partnerships for Global Impact](https://www.vactech.fi/partnering/) - Vactech partners with top academics and biotech leaders, turning cutting-edge science into impactful healthcare solutions through GLP/GCP excellence.
- [Understanding Type 1 Diabetes – For Families](https://www.vactech.fi/families/) - Type 1 diabetes is an autoimmune disease in children. Vactech develops a preventive vaccine to ensure a healthier future for children and families.
- [Vactech Oy Privacy Policy](https://www.vactech.fi/privacy-policy/)
- [Let’s Shape the Future of Health Together](https://www.vactech.fi/contact-us/) - We’re open to new ideas and collaborations. If you’d like to learn more about our company, products or technology, please don’t hesitate to contact us.
- [Revolutionizing Immune Health](https://www.vactech.fi/about-vactech/) - Vactech develops breakthrough vaccines and diagnostics for type 1 diabetes, celiac disease, and enterovirus-related conditions—shaping the future of health.
- [Next-Generation Virus-Like Particle Technology](https://www.vactech.fi/vlp-imavac/) - Vactech’s IMAVAC™ uses virus-like particles to safely trigger strong immune responses, enabling effective, non-infectious vaccine development.
- [Antiviral Innovations Targeting Celiac Disease](https://www.vactech.fi/celiac-disease/) - Celiac disease stems from immune response to gluten in genetically susceptible people; enteroviruses may trigger it. Vactech offers antiviral tools.
- [Patented Diagnostics](https://www.vactech.fi/diagnostics/) - Vactech holds patents for detecting enteroviruses linked to type 1 diabetes and celiac disease, enabling early risk identification and targeted interventions.
- [Building a Healthier Future Together](https://www.vactech.fi/investors/) - Vactech pioneers vaccines for type 1 diabetes and beyond, with strong IP, global partners, and high market potential—positioning us as a standout investment.
- [Enteroviruses Are a Key Target for Disease Prevention](https://www.vactech.fi/enteroviruses/) - Enteroviruses cause illnesses from mild colds to severe disease. Vaccines like those for polio show the promise of new, safe prevention for other strains.
- [Global Impact of Type 1 Diabetes](https://www.vactech.fi/type-1-diabetes/) - Type 1 diabetes is a lifelong disease often diagnosed in youth. With no cure, it places a major burden on patients, families, and global healthcare systems.
- [News & Press Releases](https://www.vactech.fi/news-press-releases/) - Stay updated on Vactech’s latest news and breakthroughs, including the world’s first preventive type 1 diabetes vaccine and other innovative solutions.

## Uutiset

- [New publication supports durable immune response and favorable long-term safety profile of PRV-101](https://www.vactech.fi/news/new-publication-supports-durable-immune-response-and-favorable-long-term-safety-profile-of-prv-101/) - A new peer-reviewed publication in Open Forum Infectious Diseases reports results from an extended follow-up of the first-in-human Phase 1 PROVENT trial of PRV-101, a pentavalent vaccine candidate targeting coxsackieviruses B (CVB1–5), being developed by Vactech. The follow-up evaluated participants approximately two years after immunization to assess long-term immune response and safety. The results demonstrate
- [Vactech releases a new video explaining the science behind PRV-101 vaccine](https://www.vactech.fi/news/vactech-releases-a-new-video-explaining-the-science-behind-prv-101-vaccine/) - Tampere, Finland — 13 April 2026 — Vactech Oy today announced the release of a new educational video describing the scientific rationale behind PRV-101, Vactech’s investigational multivalent vaccine designed to prevent Coxsackievirus B infections and reduce the risk of type 1 diabetes (T1D). Type 1 diabetes is an autoimmune disease in which insulin-producing beta cells
- [Vactech Oy is advancing its PRV-101 development program toward the next clinical milestone](https://www.vactech.fi/news/vactech-oy-is-advancing-its-prv-101-development-program-toward-the-next-clinical-milestone/) - PRV-101 program advances: Phase 1b preparations progressing well and the manufacturing of clinical trial supplies initiated Tampere, Finland – Vactech Oy is advancing its PRV-101 development program toward the next clinical milestone. Following the successful completion of the Phase 1a clinical study, the company has initiated preparations for the upcoming Phase 1b trial. These activities
- [Vactech Opens New Research Hub at Tampere University’s Kauppi Campus](https://www.vactech.fi/news/vactech-opens-new-research-hub-at-tampere-universitys-kauppi-campus/) - Vactech Oy has opened a new Research Hub at Tampere University’s Kauppi biocampus, further strengthening its role in the development of next-generation vaccines and vaccine technologies. The Kauppi campus hosts around 600 experts, and together with Tampere University Hospital it forms a leading Finnish cluster for medicine, biosciences and health sciences, where top researchers and
- [New Global Estimates of Type 1 Diabetes Prevalence and Future Projections](https://www.vactech.fi/news/new-global-estimates-of-type-1-diabetes-prevalence-and-future-projections/) - A new study published in Diabetes Research and Clinical Practice provides updated global estimates of type 1 diabetes (T1D) prevalence, incidence, and mortality for 2025. The findings highlight the urgent need for preventive and therapeutic innovations to address this growing challenge. According to the analysis, 9.5 million people worldwide are living with T1D in 2025,
- [Vactech Joins ENT1DEP Project to Advance Research on Enteroviruses and type 1 diabetes](https://www.vactech.fi/news/vactech-joins-ent1dep-project-to-advance-research-on-enteroviruses-and-type-1-diabetes/) - Tampere, Finland – 3rd of September 2025 – Vactech Oy is proud to announce its acceptance as a member of the ENT1DEP project (Enterovirus-linked type 1 diabetes Exposed – mechanisms and Prevention), an ambitious European initiative that aims to transform our understanding of how enterovirus (EV) infections contribute to the development of type 1 diabetes
- [New Insights into the Role of Enteroviruses in Type 1 Diabetes](https://www.vactech.fi/news/new-insights-into-the-role-of-enteroviruses-in-type-1-diabetes/) - In type 1 diabetes (T1D), the insulin-producing beta cells of the pancreas are destroyed, leading to a lifelong need for insulin treatment. Recent research has provided compelling evidence linking enterovirus infection to the development of T1D. A groundbreaking collaboration across multiple laboratories studied pancreatic tissue from over 200 organ donors to explore the presence of
- [Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer](https://www.vactech.fi/news/vactech-appoints-dr-tero-valimaa-as-new-chief-executive-officer/) - Experienced Leader Brings Over 25 Years of Pharmaceutical and Medical Device Expertise to Vactech Tampere, Finland, October 19, 2023 — Vactech Ltd., a leading biotechnology company specializing in vaccine development and medical innovation, is pleased to announce the appointment of Dr. Tero Välimaa as its new Chief Executive Officer, effective immediately. Dr. Välimaa is a highly accomplished professional
- [The results of the PRV-101 vaccine Phase I trial published in Diabetologia.](https://www.vactech.fi/news/the-results-of-the-prv-101-vaccine-phase-i-trial-published-in-diabetologia/) - Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial Read article (external site)
- [Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101](https://www.vactech.fi/news/vactech-announces-positive-final-results-from-first-in-human-study-of-coxsackievirus-b-vaccine-candidate-prv-101-2/) - PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines against Type 1 Diabetes and other immune-mediated diseases, announced today that as a result of a strategic partnership between Vactech
- [Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101](https://www.vactech.fi/news/vactech-announces-positive-final-results-from-first-in-human-study-of-coxsackievirus-b-vaccine-candidate-prv-101/) - PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Positive results support further development activities Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines against Type 1 Diabetes and other immune-mediated diseases, announced today that as a result of a strategic
- [Vactech announces positive interim results from First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 against Type 1 Diabetes](https://www.vactech.fi/news/vactech-announces-positive-interim-results-from-first-in-human-study-of-coxsackievirus-b-vaccine-candidate-prv-101-against-type-1-diabetes/) - PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Positive results support further development activities Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines against Type 1 Diabetes and other immune-mediated diseases, announced today that as a result of a strategic
- [Vactech announces that the First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 has been initiated](https://www.vactech.fi/news/vactech-announces-that-the-first-in-human-study-of-coxsackievirus-b-vaccine-candidate-prv-101-has-been-initiated/) - Potential to be the first vaccine for the prevention of coxsackievirus B, a presumed infectious trigger in the development of Type 1 Diabetes (T1D) and Celiac Disease Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines against Type 1 Diabetes and other immune-mediated diseases, announced today that as a result
- [Vactech and Provention Bio announce publication of proof-of-concept data for a preclinical prototype of coxsackievirus B vaccine](https://www.vactech.fi/news/vactech-and-provention-bio-announce-publication-of-proof-of-concept-data-for-a-preclinical-prototype-of-coxsackievirus-b-vaccine/) - Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine -- The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models -- Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine Read article (external
- [Vactech announces issuance of US patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes](https://www.vactech.fi/news/vactech-announces-issuance-of-us-patent-for-multi-cbv-vaccine-for-preventing-or-treating-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted an US Patent 10,258,685 related to a multivalent CBV vaccine for preventing or treating Type 1 Diabetes. Field of
- [A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of Type 1 Diabetes](https://www.vactech.fi/news/a-coxsackievirus-b-vaccine-protects-against-virus-induced-diabetes-in-an-experimental-mouse-model-of-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that a Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of Type 1 Diabetes and the research results has been published in the scientific journal of
- [Vactech announces a US-based strategic partnership and clinical development program focused on intercepting and preventing the onset of Type 1 Diabetes](https://www.vactech.fi/news/vactech-announces-a-us-based-strategic-partnership-and-clinical-development-program-focused-on-intercepting-and-preventing-the-onset-of-type-1-diabetes/) - Lead asset out-licensed to Provention Bio, Inc. for the development of a vaccine preventing Type 1 Diabetes by targeting coxsackievirus B infections Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines against Type 1 Diabetes and other immune-mediated diseases, today announced it has entered into a strategic partnership with Provention
- [Enteroviral infections detected in the pancreases of living patients newly diagnosed with Type 1 Diabetes](https://www.vactech.fi/news/enteroviral-infections-detected-in-the-pancreases-of-living-patients-newly-diagnosed-with-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that enterovirus infection has been detected in the pancreases of living patients newly diagnosed with Type 1 Diabetes and the research results has been published in the scientific journal of
- [Vactech announces issuance of EPO patent for Use of Enterovirus for Diagnostics, Treatment and Prevention on Celiac Disease](https://www.vactech.fi/news/vactech-announces-issuance-of-epo-patent-for-use-of-enterovirus-for-diagnostics-treatment-and-prevention-on-celiac-disease/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the European Patent Office has issued EPO Patent 2,225,366 related to diagnostics, and treatment and prevention of Celiac Disease. Field of the invention The invention relates to diagnostics, and
- [Vactech announces issuance of EPO patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes](https://www.vactech.fi/news/vactech-announces-issuance-of-epo-patent-for-multi-cbv-vaccine-for-preventing-or-treating-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the European Patent Office has intended to grant an EPO Patent 2768527 related to a multivalent CBV vaccine for preventing or treating Type 1 Diabetes. Field of the invention
- [Vactech announces issuance of EPO patent for Diagnostic Assay for Type 1 Diabetes](https://www.vactech.fi/news/vactech-announces-issuance-of-epo-patent-for-diagnostic-assay-for-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the European Patent Office has issued EPO Patent 2588134 related to a diagnostic assay for Type 1 Diabetes (T1 D) and predicting the risk of contracting the disease. Field
- [Vactech announces issuance of EPO patent for Prevention of Allergic Sensitization](https://www.vactech.fi/news/vactech-announces-issuance-of-epo-patent-for-prevention-of-allergic-sensitization/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the European Patent Office has issued EPO Patent 2,114,448 related to decreasing the risk of allergic sensitization and its progression to clinical illnesses. Field of the invention The present
- [A new vaccine against Coxsackievirus B1 shows good efficacy and reveals no risk for accelerated diabetes development in mouse models](https://www.vactech.fi/news/a-new-vaccine-against-coxsackievirus-b1-shows-good-efficacy-and-reveals-no-risk-for-accelerated-diabetes-development-in-mouse-models/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that a preclinical study on the efficacy and safety of an experimental vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models but protects completely the
- [Vactech announces issuance of Canadian patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases](https://www.vactech.fi/news/vactech-announces-issuance-of-canadian-patent-for-prevention-of-type-1-diabetes-and-other-non-polio-enterovirus-diseases/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the Canadian Intellectual Office has issued CA Patent 2,376,923 covering prevention of Type 1 Diabetes Mellitus and other non-polio enterovirus diseases by eliminating the risk effect of enterovirus infections.
- [Risk association between coxsackieviruses and Type 1 Diabetes confirmed in Different European Populations](https://www.vactech.fi/news/risk-association-between-coxsackieviruses-and-type-1-diabetes-confirmed-in-different-european-populations/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the risk association between coxsackieviruses and Type 1 Diabetes in different European populations has been confirmed and published in the scientific journal of the American Diabetes Association (Diabetes journal).
- [Research results indicates risk association between coxsackieviruses and Type 1 Diabetes](https://www.vactech.fi/news/research-results-indicates-risk-association-between-coxsackieviruses-and-type-1-diabetes/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that significant results on the risk association between coxsackieviruses and Type 1 Diabetes has been published in the scientific journal of the American Diabetes Association (Diabetes journal). Publication: http://diabetes.diabetesjournals.org/content/63/2/446.long Study setup
- [Vactech announces issuance of US patent for Prevention of Allergic Sensitization](https://www.vactech.fi/news/vactech-announces-issuance-of-us-patent-for-prevention-of-allergic-sensitization/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the United States Patent and Trademark Office has issued US Patent 8,182,805 B2 related to decreasing the risk of allergic sensitization and its progression to clinical illnesses. Field of
- [Vactech announces issuance of a completing US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases](https://www.vactech.fi/news/vactech-announces-issuance-of-a-completing-us-patent-for-prevention-of-type-1-diabetes-and-other-non-polio-enterovirus-diseases/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the United States Patent and Trademark Office has issued US Patent 7,972,592 B2 covering prevention of Type 1 Diabetes Mellitus and other non-polio enterovirus diseases by eliminating the risk
- [Vactech announces issuance of US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases](https://www.vactech.fi/news/vactech-announces-issuance-of-us-patent-for-prevention-of-type-1-diabetes-and-other-non-polio-enterovirus-diseases/) - Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the United States Patent and Trademark Office has issued US Patent 7,090,855 B1 covering prevention of Type 1 Diabetes Mellitus and other non-polio enterovirus diseases by eliminating the risk